Amgen Inc. (NASDAQ:AMGN)’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Saint Francis Hospital is partnering with the Our Blood Institute to hosts the first mobile platelet drive in northeast ...

In vivo platelet activation and related pathways may be linked to small airways disease and pulmonary vascular changes in smokers.

Results of a randomized, placebo-controlled study demonstrated avatrombopag achieved the primary endpoint of platelet response in heavily pretreated pediatric patients with persistent or chronic ITP.